Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib

Journal of Clinical Pharmacology

Volumn 47, Issue 10, 2007, Pages 1342-1346

  Schwartz, Jules I ^a   Agrawal, Nancy G B ^a   Kher, Uma A ^a   DeSmet, Marina ^a   Cavanaugh Jr , Paul F ^a   Guillaume, Michel ^b   Ebel, David L ^a   Merschman, Shelia A ^a   Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Pharmacologie Clinique   (France)

Author keywords

Antacids; Cyclooxygenase 2; Etoricoxib

Indexed keywords

ALUMINUM HYDROXIDE; ANTACID AGENT; CALCIUM CARBONATE; ETORICOXIB; MAGNESIUM HYDROXIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; HUMAN; HUMAN EXPERIMENT; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; OPTIMAL DRUG DOSE; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; VARIANCE;

ADULT; AGED; ALUMINUM HYDROXIDE; ANALYSIS OF VARIANCE; ANTACIDS; AREA UNDER CURVE; CALCIUM CARBONATE; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; FEMALE; HUMANS; MAGNESIUM HYDROXIDE; MALE; MIDDLE AGED; PYRIDINES; SULFONES;

EID: 34648833447     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007304777     Document Type: Article

References (25)

1. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000 ; 43: 1905-1915.
2. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 1996 ; 39: 713-722.
3. Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharmacol. 2006 ; 47 (suppl 1). S60 - S66.
4. Laine L. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms. Rev Gastroenterol Disord. 2003 ; 3 (suppl 4). S30 - S39.
5. Larkai EN, Smith JL, Lidsky MD, Sessoms SL, Graham DY Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol. 1989 ; 11: 158-162.
6. Zhao SZ, Arguelles LM, Dedhiya SD, Morgan DG Healthcare utilization associated with dyspepsia in patients with arthritis. Am J Manag Care. 1999 ; 5: 1285-1295.
7. Rahme E., Toubouti Y., Hunsche E. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada. Rheumatology (Oxford). 2006 ; 45: 903-910.
8. Zhao SZ, Wentworth C., Burke TA, Makuch RW Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf. 2004 ; 13: 277-287.
9. Moayyedi P., Soo S., Deeks J., Delaney B., Innes M., Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006 ;(4). CD001960.
10. Maton PN, Burton ME Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999 ; 57: 855-870.
11. Matsumoto AK, Cavanaugh PF Jr. Etoricoxib. Drugs Today (Barc). 2004 ; 40: 395-414.
12. Ramey DR, Watson DJ, Yu C., Bolognese JA, Curtis SP, Reicin AS The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005 ; 21: 715-722.
13. Baraf HS, Fuentealba C., Greenwald M., et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) Trial. J Rheumatol. 2007 ; 34: 408-420.
14. Laine L., Curtis SP, Cryer B., Kaur A., Cannon CP Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007 ; 369: 465-473.
15. Watson DJ, Bolognese JA, Yu C., Krupa D., Curtis S. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin. 2004 ; 20: 1899-1908.
16. 1983 Metropolitan height and weight tables. Stat Bull. 1983 ; 64: 3-9.
17. Agrawal NG, Porras AG, Matthews CZ, et al. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol. 2003 ;43: 268-276.
18. Tablets ARCOXIA™ (etoricoxib, MSD) [Worldwide Product Circular] Whitehouse Station, NJ: Merck & Co Inc; 2007.
19. Yeh KC, Remphrey K. A simplex optimization program. Pharm Res. 1990 ; 7 (suppl 9). S - 244.
20. Reginster J., Malmstrom K., Mehta A., et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomized studies of osteoarthritis patients. Ann Rheum Dis. 2007 ;66: 945-951.
21. Leung AT, Malmstrom K., Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trail. Curr Med Res Opin. 2002 ; 18: 49-58.
22. Gottesdiener K., Schnitzer T., Fisher C., et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology. 2002 ; 41: 1052-1061.
23. Wiesenhutter CW, Boice JA, Ko A., et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005 ; 80: 470-479.
24. Bingham CO III, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford). 2007 ; 46: 496-507.
25. Curtis SP, Maldonado-Cocco J., Lozada B., et al. Characterization of the clinically effective dose range of MK-0663, a COX-2 selective inhibitor, in the treatment of rheumatoid arthritis. Arthritis Rheum. 2000 ; 43 (suppl 9). S226.